BRAF and acute lymphoblastic leukemia: Some of the approved drugs are dasatinib to treat Philadelphia chromosome-positive chronic myelogenous leukaemia (CML) and acute lymphoblastic leukaemia (ALL), dabrafenib to treat BRAF-positive cancers and ixabepilone aimed at breast cancer (figure 1) [6,7].